DESCRIPTION: Therapeutic and prevention clinical trials in cancer and other
major diseases with mortality or irreversible morbidity are typically
monitored to detect early evidence of benefit or harm for ethical and
scientific reasons. However, repeated interim analyses using conventional
statistical methods will increase the likelihood of false positive claims of
treatment effect. In 1983, Lan and DeMets (Biometrika) extended earlier
work of Pocock (1977), O'Brien and Fleming (1979) and others by proposing a
flexible group sequential plan using an alpha spending function. In the
previous proposal, we extended the application of the alpha spending
function to repeated measure designs using linear mixed effects regression
models and ordinal regression moods. Trials early may exaggerate treatment
benefits or harm even though the hypothesis of no effect has been rejected.
In this proposal, we further evaluate the degree of bias in the estimate of
treatment effect and propose correction estimators for the linear mixed
effects model and the proportional hazards model in survival. However, use
of such models in either a sequential or non-sequential setting require that
certain model assumptions be met, such as linearity or proportional hazards.
We also propose developing sequential versions existing goodness of fit
tests for these models such that inadequacy of the models can be identified
early in the interim monitoring. Both the bias correction estimates and the
sequential goodness of fit tests will be evaluated for common spending
functions, various patterns of interim analyses, size of trials and
robustness to model assumptions.
Error Notice
The database may currently be offline for maintenance and should be operational soon. If not, we have been notified of this error and will be reviewing it shortly.
We apologize for the inconvenience.
- The DCCPS Team.